
|Videos|September 10, 2019
The Future of Personalized Therapy in Advanced HCC
Advertisement
Key Takeaways:
Novel approaches in the treatment of advanced hepatocellular carcinoma, such as using modified T-cell receptors to attack liver tumors with alpha fetoprotein expression.
Biomarker-based approaches to target the FGF19—FGFR4 signaling pathway, with a new generation of molecules in patients with hepatocellular carcinoma and high-FGF19 amplification or expression.
Moving toward a more personalized approach in the treatment of hepatocellular carcinoma.
Ensuring patients with hepatocellular carcinoma are not decompensated during initial locoregional therapy, so they may benefit from the sequencing of current and future therapies.
Advertisement
Related to this article

In case you missed any, read a recap of the episodes of OncLive On Air that aired in September 2026.

Japan approved Optune Pax plus gemcitabine and nab-paclitaxel for unresectable locally advanced pancreatic cancer.

A New England Journal of Medicine report describes complete hepatoblastoma regression in a 3-year-old treated with a novel immunotherapy.

Benjamin Weinberg, MD, discusses the FDA approval of daraxonrasib, RASolute 302 survival data, safety considerations, and future RAS-targeted therapies in pancreatic cancer.

The FDA approved lirafugratinib in FGFR2+ cholangiocarcinoma and belzutifan plus lenvatinib in advanced ccRCC, and more.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

Results from an early-stage clinical trial found encouraging outcomes in newly diagnosed pancreatic cancer that had spread to distant organs.
Advertisement
Advertisement
Trending on OncLive
1
Epcoritamab Plus R-CHOP Meets PFS End Point in Newly Diagnosed DLBCL
2
‘Our Impact Will Be Broad and Transformative’: Wells Messersmith, MD, Takes the Reins at CU Anschutz Cancer Center
3
FDA Approves Pirtobrutinib for Previously Untreated CLL/SLL
4
Berzosertib Plus Carboplatin Fails to Improve Responses in Pretreated mCRPC
5



